^
    Back
    Association details:
    Biomarker:KIT D820A
    Cancer:Gastrointestinal Stromal Tumor
    Drug:imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2022
    Title:

    Exploration of drug resistance in advanced gastrointestinal stromal tumor.

    Published date:
    01/18/2022
    Excerpt:
    Detection rate of ctDNA in imatinib-resistant patients was 57% (31/54). Among these 31 patients, 12 (39%) showed KIT gene mutation...Among these 19 patients, 10 (53%) showed KIT gene mutation (including 5 with the known drug-resistant KIT mutations, 4 of these patients exhibited single-drug resistance, while 1 showed multi-drug resistance due to mutations mainly in Exon 13 V654A, Exons 17 D820A, and D820G).
    DOI:
    10.1200/JCO.2022.40.4_suppl.662